Generics now dominate the semaglutide market worldwide, pushing brand‑name sales into a narrower niche. Industry trackers note that after a steep rise in India, sales of generic weight‑loss drugs have tapered and overall demand has stabilised. Recent research finds the drug’s weight‑loss effect differs widely between users, with some seeing strong results and others modest change. Novo Nordisk announced a partnership with Vivani to create a long‑acting semaglutide implant that could release the drug over a few months. The development aims to give the company a new option as generic competitors claim more of the market. Analysts say the implant could alter treatment patterns if clinical trials confirm its safety.